CompletedNot Applicable

Betamethasone and Severity of Hyaline Membrane Disease

France127 participantsStarted 2012-01-12

Plain-language summary

Primary purpose: to study the relationship between betamethasone placental transfer and the occurrence and severity of the Hyaline Membrane Disease.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant women who received at least a first injection of Celesten in the prevention of MMH. * A one-term\> 27 SA, * Major Patients \> or = 18 years old * Informed Consent Form signed Exclusion Criteria: * Patients undergoing treatment with corticosteroids in the long term

What they're measuring

Number of neonates with hyaline membrane disease

Timeframe: 3 days

Trial details

NCT IDNCT01854840

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-06-30

View on ClinicalTrials.gov More Pregnant Women Receive Celesten trials